ORANGE COUNTY, Calif., April 28 /PRNewswire-FirstCall/ -- Beckman Coulter, Inc. (NYSE:BEC - News), a leading developer, manufacturer and marketer of products that simplify, automate and innovate complex biomedical testing, announced today first quarter ended March 31, 2010 results. Reported first quarter revenue, including $115.7 million from the recent Olympus Diagnostics acquisition (Olympus), was $881.1 million, up 27.4% over prior year quarter, or 23.6% in constant currency. On a constant currency basis, recurring revenue increased 23.7%. Recurring revenue, excluding the impact of Olympus, grew 8.4% in constant currency. Reported net earnings were $38.7 million, or $0.54 per fully diluted share. Adjusted for special items related primarily to restructuring charges and acquisition costs, and excluding Olympus intangibles amortization, net earnings were $61.8 million, or $0.86 per fully diluted share, an increase of 21% over prior year quarter. (See “Non-GAAP Financial Measures” and “Reconciling Items to Non-GAAP Financial Measures.”)
